ArticleInternational orthopaedics2026
Risk factors for postoperative recurrence of sacral chordoma: an eleven-year single-centre retrospective study.
Article in International orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeChordoma is a rare, low-grade malignant bone tumour that most commonly arises in the sacrococcygeal region. Reported prognostic factors for recurrence are inconsistent and the role of postoperative adjuvant treatment is undefined. We investigated risk factors for recurrence in a consecutive single-centre cohort of sacral chordoma in which R0 resection was achieved in every patient.
methodsWe retrospectively reviewed 34 consecutive patients with sacral chordoma treated with curative resection at our centre between 2013 and 2024. Clinical, surgical, adjuvant and follow-up data were recorded. Recurrence-free survival (RFS) was estimated using the Kaplan-Meier method, and independent risk factors for recurrence were identified using multivariate Cox regression.
resultsThe cohort comprised 24 men and ten women (mean age 62.1 years). Recurrence occurred in 19 of 34 patients (55.9%) after a median follow-up of 36 months; median RFS was 33 months (95% CI 16.7-49.3) and nine patients (47.4%) developed distant metastases. Maximum tumour diameter ≥ 65 mm (HR 3.42, 95% CI 1.18-9.92; p = 0.024) and a history of previous surgery (HR 4.57, 95% CI 1.52-13.73; p = 0.007) were independent risk factors for recurrence, whereas postoperative targeted therapy was associated with lower recurrence risk (HR 0.31, 95% CI 0.10-0.94; p = 0.038).
conclusionRecurrence of sacral chordoma was common even after R0 resection. Large tumour diameter and previous surgery were independent risk factors for recurrence. The association between postoperative targeted therapy and lower recurrence risk should be interpreted with caution because treatment was not randomised.
Indexed as
Identifiers
42860435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.